» Articles » PMID: 38361401

Diagnostic Accuracy of Serum Protein Induced by Vitamin K Absence (PIVKA-II), Serum A-fetoprotein and Their Combination for Hepatocellular Carcinoma Among Caucasian Cirrhotic Patients with Diagnostic or Non-diagnostic Serum A-fetoprotein Levels

Overview
Journal Cancer Med
Specialty Oncology
Date 2024 Feb 16
PMID 38361401
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim of our study was to evaluate the accuracy of serum biomarkers (AFP/PIVKA-II) and their combination in HCC diagnosis among Caucasian cirrhotic patients.

Methods: Serum AFP/PIVKA-II levels were evaluated in 218 cirrhotics (163 males, 118 CTP-A, 66 ALBI-I, 111 with varices, 63 with diabetes) with (n = 90) or without (n = 128) HCC. Patients with HCC were categorized to BCLC Stage 0/A (n = 12), B (n = 21), C (n = 48), and D (n = 9).

Results: The two groups were comparable for all baseline parameters except for age, platelets, and diabetes presence. Median levels of AFP (239.1 vs. 4.0 ng/mL) and PIVKA-II (4082.7 vs. 45.8 mAU/mL) were both significantly higher in HCC group compared to controls (p < 0.001). AUROC and cutoff value for HCC diagnosis were 88%/12.35 ng/mL (AFP) and 84.4%/677.13 mAU/mL (PIVKA-II), whereas their combination showed better diagnostic accuracy (AUROC = 90.2%). The diagnostic accuracy of each biomarker separately was moderate or good in BCLC-0/A/B and was excellent only for BCLC-C patients (AFP: AUROC = 94.3%, cutoff = 12.35 ng/mL and PIVKA-II: 91.3%, 253.51 mAU/mL) whereas their combination presented quite acceptable results in BCLC-B (AUROC = 92.4%) and BCLC-C (AUROC = 95.7%). Excluding HCC patients with high AFP (above 400 ng/mL), the diagnostic accuracy of each biomarker separately and their combination was moderate/good in all groups, except for their combination in BCLC-C (AUROC = 90.5%).

Conclusions: Each biomarker separately showed acceptable accuracy for detecting HCC in cirrhotic patients and excellent for those in BCLC-C stage. The combination of the biomarkers presented excellent results in BCLC-B/C patients. The diagnostic accuracy of PIVKA-II and the combination of the two biomarkers in patients expressing low/non-diagnostic AFP levels was good in BCLC-B and excellent in BCLC-C patients.

Citing Articles

Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma.

Guarneri V, Loggi E, Ramacieri G, Serra C, Vukotic R, Vitale G Cancers (Basel). 2025; 17(2).

PMID: 39857948 PMC: 11763969. DOI: 10.3390/cancers17020167.


Blood biomarkers of hepatocellular carcinoma: a critical review.

Zhao J, Hu Z, Zheng X, Lin Y, Liu X, Zhang J Front Cell Dev Biol. 2024; 12:1489836.

PMID: 39650722 PMC: 11621223. DOI: 10.3389/fcell.2024.1489836.


Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels.

Syriha A, Pantzios S, Mandilara D, Galanis P, Stathopoulou I, Barla G Cancer Med. 2024; 13(3):e6825.

PMID: 38361401 PMC: 10904976. DOI: 10.1002/cam4.6825.

References
1.
Singal A, Zhang E, Narasimman M, Rich N, Waljee A, Hoshida Y . HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022; 77(1):128-139. PMC: 9232881. DOI: 10.1016/j.jhep.2022.01.023. View

2.
Liu S, Sun L, Yao L, Zhu H, Diao Y, Wang M . Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. J Clin Med. 2022; 11(17). PMC: 9456633. DOI: 10.3390/jcm11175075. View

3.
Syriha A, Pantzios S, Mandilara D, Galanis P, Stathopoulou I, Barla G . Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels. Cancer Med. 2024; 13(3):e6825. PMC: 10904976. DOI: 10.1002/cam4.6825. View

4.
Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G . PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore). 2017; 96(26):e7266. PMC: 5500043. DOI: 10.1097/MD.0000000000007266. View

5.
Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View